Articles On Botanix Pharmaceuticals (ASX:BOT)

Since the start of March, six clinical trials involving cannabis treatments around the world have been halted or cancelled altogether due to COVID19 pandemic but 179 are still recruiting, according to the US registry ClinicalTrials.com. Mor...

North American pot stocks are roaring back from lows in March but the same cannot be said for their antipodean counterparts, many of which continue to wallow. The New Cannabis Ventures Global Cannabis Stock Index soared 26 per cent last wee...

The cohort of 33 pot (and pot-adjacent) stocks tracked by Stockhead followed the broader market higher in April, as the ASX200 climbed 8.8 per cent to post its best monthly gain in 32 years. The big news in cannabis this week came in the fo...

Investors have cheered confirmation the US FDA granted Botanix Pharmaceuticals' (ASX:BOT) first antibacterial product (BTX 1801) approval for the prevention of post-surgical infections.

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

This is a significant milestone for Botanix as BTX 1801 is the first cannabinoid-based program to receive the designation globally and represents a strong endorsement of Botanix’s data.

In amidst the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the FDA to fast track its first antibacterial product, B...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

As fears surrounding the Coronavirus drive the markets down, one ASX-listed pot stock could triumph amid the COVID-19 crisis. The Coronavirus, now known as COVID-19, emerged from Wuhan in China last December and has since sent shockwaves th...

Synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) has unveiled the next phase of development for its cannabinoid antimicrobial platform and lead program BTX 1801. Earlier today, Botanix declared it had achieved “significant p...

Neuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its Rett syndrome treatment, a serious and rare neurological disorder mainly affecting little girls. The US Food and Drug Administration (FDA) gr...

As market watchers would know, cannabis stocks globally have had a wild ride over the last three years. The volatility is a natural by-product of any frontier market – full of stops and starts as companies try to build out their business mo...

With the health and life science sector being the ASX’s top performer last year, Western Australia is keen to join the party. The state government has formed an Industry Reference Group to come up with a five-year growth plan for the indust...

Only one prescription for medical marijuana has been issued by a doctor in the Northern Territory, according to Minister for Health Natasha Fyles. In a submission to the Senate inquiry into barriers to patient access to marijuana, Fyles sai...

For an industry that’s projected to reach $US20 billion ($29 billion) by 2024 in the US, the cannabidiol (CBD) market there is very much the wild west. A study from researcher Leafreport comparing 3500 products for the sale in the US from 5...

Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it is attending and key investor conferences in the US in January - the JP Morgan Healthcare and Dermatology Summit conferences.

Last year was a bear market for cannabis stocks globally. During 2019, the excitement that had followed the legalisation of marijuana in many jurisdictions was replaced by cautio as investors realised early forecasts weren’t necessarily ma...

On Thursday the S&P/ASX 200 index started the year on a mildly positive note. The benchmark index rose 0.1% to 6,690.6 points. Will the local share market be able to build on this on Friday? Here are five things to watch: ASX 200 expec...

This year was a difficult one for ASX cannabis shares as well as cannabis stocks globally with share prices worldwide retreating from previous highs. In Australia the medical marijuana industry remains in its infancy. Nonetheless, the init...

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

Emerging or early-stage companies offer new investment opportunities to investors, and higher returns are expected from start-ups due to their potential for growth. Investing in early-stage companies is risky; however, it offers the potenti...

Cannabis industry player Elixinol Global (ASX:EXL) will take a $2.2m profit hit when it divests its stake in a Japanese investment to focus on Western markets. The Sydney World Square company revealed overnight its subsidiary EXL Internatio...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

In the year 2019, marijuana stocks were among the hot picks for investors, despite the general market impulsiveness, strong competition and economic pressures. Recently, a green signal has been given to a bill legalising marijuana on the st...

Health care in Australia is the most diversified and dynamic sector and has the potential to generate significant revenues for the Australian economy. The health care sector comprises of companies engaged in drug development and R&D act...

In this article we are discussing five ASX-listed health care stocks, Althea Group Holdings Limited (ASX: AGH), Botanix Pharmaceuticals Limited (ASX:BOT), SDI Limited (ASX: SDI), Mach7 Technologies Limited (ASX: M7T), OncoSil Medical Limite...

Cannabis has been progressively decriminalised around the world since the early 2000s, starting with Canada granting legal access for medical purposes in 2001 and several other countries following suit. It has taken Australia 15 years to ca...

Cannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the cannabis shares have been taking a beat in the domestic markets, falling from their respective all-time highs. The table below provides you w...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

Here’s our fortnightly wrap of the major small cap health stock winners and losers.  One small cap ASX healthcare company has stormed home to top the tables at the end of October. Novita Healthcare (ASX:NHL) shares have exploded 500 per cen...

It’s been a year of highs and lows for cannabis shares. Marijuana shares were favourites of investors earlier this year but have since suffered setbacks: the vaping crisis in the United States (US) as well as issues on the home front have...

Cannabis is a fast-growing industry with a dynamic and rapidly changing prospects, the medicinal cannabis stocks are progressing on the right track to capture investors’ attention and maximum addressable market. Players dealing in medicinal...

Health care system of Australia is considered as one of the best, globally, as it delivers safe and affordable health care solutions and services to the citizens. Health care sector in Australia comprises of medical service, medical insuran...

Health care sector is one of the popular sectors among investors, as it is one of the high yielding sectors. However, at times, investors also lose their money, when health care stocks engaged in research & development activities fail t...

Pn this day in 2001, Apple announced the release of the first iPod player. The iPod became the world's biggest-selling portable media player; six years after its initial launch, Apple announced that 100 million devices had been sold. The co...

Amidst the global market fickleness, competition and economic pressure, cannabis stocks stand out as the hot pick stocks for investors.  The Cannabis stocks are gaining traction with the sector growing at a fast pace with new listings and i...

Listed cannabis stocks worldwide have pulled back from their highs lately, tainted by the vaping crisis in the US. Canopy Growth has seen its share price drift down to just above US$20 from highs of over US$50 in April. Rival Aurora Cannab...

In afternoon trade the S&P/ASX 200 index is on course to give back yesterday’s gains. At the time of writing the benchmark index is down 0.25% to 6,655.5 points. Four shares that have fallen more than most today are listed below. Here’...

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

The Elixinol Global Ltd (ASX: EXL) share price has come under significant selling pressure today after returning from a trading halt. The diversified cannabis company’s shares crashed 10% lower to $1.92 this morning. Why did the Elixinol G...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

It looks set to be a disappointing day of trade for the Botanix Pharmaceuticals Ltd (ASX: BOT) share price on Wednesday. The cannabis-focused medical dermatology company’s shares look set to be sold off after a disappointing study result....

Drug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyonda treatment on patients with late-stage prostate cancer. NOX provided an interim update on its DARRT-1 clinical trial, where patients are gi...

In the few short years since cannabis companies first floated on stock exchanges around the world, they have developed a reputation for being volatile and high risk. At the start, stocks exploded in value, peaking around the start of 2018....

Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has been awarded a new Innovation Connections Grant by federal agency AusIndustry.

Biotech company Immutep (ASX:IMM) just got some positive results in a Phase I clinical trial for its cancer-fighting treatment. Phase I trials are used to test safety of a given drug, before Phase II trials which measure effectiveness. Immu...